All News
The Immunologic Basis of Wellness in the COVID-19 Era
We indeed are living in interesting times and we all are seeking not to contract COVID-19 - this is logical. While our goal is to avoid infection, I think we all must agree that our aspirations must encompass more than disease avoidance. What we should be seeking now, as well, is more than absence of disease but rather a state of optimal wellness.
RheumNow Podcast – Pandemic Numbers (4.3.20)
Dr. Jack Cush reviews the news on COVID-19 and FDA actions this past week. Be sure to check out:
Read Article
CDC: Impact of Underlying Health Conditions Among COVID-19 Patients
The March 31 release of the Morbidity and Mortality Weekly Report (MMWR) reviews the impact of several key comorbidities, most commonly diabetes mellitus, chronic lung disease, and cardiovascular disease, as cofactors leading to worse outcomes with COVID-19 infections. Below are e
Read Article
RheumNow Podcast – New World Order (3.27.20)
Dr. Jack Cush reviews the news and COVID developments from this past week.
Read Article
Global Rheumatology Alliance Registry Will Study COVID-19
In the midst of a global pandemic of the 2019 Novel coronavirus acute respiratory disease (COVID-19), a small handful of Rheumatologists gathered on social media to collectively grapple with the impact of this virus on vulnerable populations with rheumatic disease.
COVID-19 Rheumatology News
With the COVID-19 pandemic dynamically changing, we have provided several news items germane to the Rheumatologist.
Read Article
RheumNow Podcast - Despite Corona (3.6.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Interleukin-37 Targeting in Gout
The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.
Read Article
RheumNow Podcast- Methotrexate Mechanisms (2.28.20)
Dr Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
Read Article
Why You Should Come to RheumNow Live March 13th
RheumNow Live kicks off its second annual meeting - a little, big meeting in Fort Worth - in just 2 weeks and I think you should be there.
Read Article
Shingles Vaccine Lowers Risk of CVA
Shingles infection has been historically linked to an increased risk of stroke. A new study found that Zoster Vaccine Live, one type of shingles vaccination, may prevent stroke in some older adults.
Read Article
Bimekizumab Effective in Active Psoriatic Arthritis
Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.
Read Article
RheumNow Podcast- Best Biologics (2.7.20)
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
RheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
RheumNow Podcast- A Good First Impression (1.24.20)
Dr Jack Cush comments on this week's journal articles, reviews and studies.
Read Article
Low Risk of Inflammatory Arthritis in Hidradenitis Suppurativa Patients
JAMA Dermatology reports that after the onset and diagnosis of hidradenitis suppurativa (HS), such patients have a higher risk of certain forms inflammatory arthritis.
Read Article
QD Clinic - Hepatitis B and Biologics
QD Clinic - Lessons from the clinic
Active HBV infection (HGsAg+) on anti-viral therapy but needs a biologic - what should you use?
RheumNow Podcast- The Down Side of Steroids (1.17.20)
Dr. Jack Cush reviews the journal reports and news from RheumNow.com.
Be sure to register for RheumNow Live 3/13/2020 in Fort Worth
Rheumnow.live.
TULIP2 - Anifrolumab Succeeds in Lupus
NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.
Steroids Up the Risk of Organ Damage in SLE
Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.
Read Article